HOME >> BIOLOGY >> NEWS
Chemists unlock secret to activating tumor suppressor gene

Researchers have discovered the way to activate a key anti-cancer signal that goes AWOL in several gynecologic and brain cancers.

Since the late 1990s, researchers have known that a gene called PTEN (short for phosphatase and tensin homolog on chromosome 10) encodes a signaling protein that suppresses tumor growth. What wasn't known, however, was what mechanism activated PTEN. The answer was found by a group of researchers led by University of Illinois at Chicago chemistry professor Wonhwa Cho. They report their findings in the June 9 online edition of the Proceedings of the National Academy of Sciences.

"The role of PTEN is to counterbalance the action of an enzyme that induces cell growth," said Cho. "Over-activation of the enzyme can lead to cancer. So if you lose a PTEN gene and its cellular activity, the cell goes out of control. It's like a car with an accelerator but without the brakes."

It was generally thought that PTEN was activated by binding to other proteins, giving it a signal to interact with the cell membrane. But Cho said that's not the case.

Cho's group found that PTEN itself can be activated by phosphorylation, or the chemical addition of a phosphate tag.

"We found that the phosphorylation of certain sites of the PTEN protein worked as a switch to completely change its electrostatic property," said Cho. "It switched from being neutral to positively charged, then recognized the opposite charge on the membrane to bind there." Once the bind took hold, the cancer suppression action went to work.

Cho's laboratory used a biophysical technique called surface plasmon resonance analysis and cellular microscopic analysis of green fluorescence protein-labeled PTEN to unlock the secret of its activation. The UIC chemist believes the mechanism described for PTEN is a relatively common way to regulate membrane binding and activation of many cellular proteins involved in cell signaling and membrane traffickin
'"/>

Contact: Paul Francuch
francuch@uic.edu
312-996-3457
University of Illinois at Chicago
10-Jun-2003


Page: 1 2

Related biology news :

1. Chemists at four pharmaceutical companies named Heroes for treating childhood conditions
2. Chemists create unusual lariat RNA, a key intermediate in biological splicing
3. American Institute of Chemists names Ralph Hirschmann AIC Gold Medalist
4. Chemists explore the shape of the key that signals cell division in cancer cells
5. Nanoencapsulation: Chemists at TSRI discover a new and simple way of controlling reactions
6. Chemists characterize regulators of zinc intake and export in cells
7. Chemists spin materials to improve magnetic resonance data
8. Chemists describe "zipper teeth" of DNA molecules -- publish results in the journal Nature
9. Chemists report new approach to synthetic fragments of medically important Heparin
10. Chemists hold national meeting August 22-26
11. Chemists hold national meeting August 22-26 in New Orleans

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
Breaking Biology Technology:
Cached News: